Poorly Differentiated Thyroid Carcinoma Clinical Trial
Official title:
A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.
Subjects will receive the treatment regimen as follow:
intravenous infusion of liposomal doxorubicin 35 mg/m2, d1; cisplatin 75 mg/m2, drip, total
dose should be carried out on d1-3; once every 21days, for 6 cycles. Stop the treatment if
the patients have progressed or intolerated to the toxicity. The primary endpoint is disease
control rate(DCR), the secondary endpoint is overall survival (OS), progression-free survival
(PFS), safety and quality of life assessment(QoL).
;